

Title (en)
COMPOSITIONS AND METHODS FOR SUPPRESSION OF CARBONIC ANHYDRASE ACTIVITY

Title (de)
ZUSAMMENSETZUNGEN UND VERFAHREN ZUR UNTERDRÜCKUNG VON CARBOANHYDRASEAKTIVITÄT

Title (fr)
COMPOSITIONS ET MÉTHODES INHIBANT L'ACTIVITÉ DE L'ANHYDRASE CARBONIQUE

Publication
EP 2847175 A4 20160420 (EN)

Application
EP 13787577 A 20130203

Priority
• IN 1810CH2012 A 20120508
• IB 2013050899 W 20130203

Abstract (en)
[origin: WO2013167994A1] Provided are the compounds of formula (I) or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula (I), and methods for treating or preventing or modulating carbonic anhydrase activity in a disease may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of glaucoma, epileptic seizures, Idiopathic intracranial hypertension (pseudotumor cerebri), altitude sickness, cystinuria, periodic paralysis and dural ectasia, congestive heart failure, drug induced edema, diuretic, intermittent claudication resulting from obstructed arteries in the limbs, and vascular dementia.

IPC 8 full level
A61K 31/433 (2006.01); **A61P 27/06** (2006.01); **C07D 285/135** (2006.01)

CPC (source: CN EP)
A61P 1/08 (2017.12 - EP); **A61P 1/16** (2017.12 - EP); **A61P 3/10** (2017.12 - EP); **A61P 7/00** (2017.12 - EP); **A61P 7/10** (2017.12 - EP); **A61P 9/00** (2017.12 - EP); **A61P 9/04** (2017.12 - EP); **A61P 9/10** (2017.12 - EP); **A61P 11/06** (2017.12 - EP); **A61P 11/08** (2017.12 - EP); **A61P 13/02** (2017.12 - EP); **A61P 13/12** (2017.12 - EP); **A61P 15/08** (2017.12 - EP); **A61P 19/10** (2017.12 - EP); **A61P 25/00** (2017.12 - EP); **A61P 25/04** (2017.12 - EP); **A61P 25/08** (2017.12 - EP); **A61P 25/28** (2017.12 - EP); **A61P 27/06** (2017.12 - EP); **A61P 35/00** (2017.12 - EP); **A61P 43/00** (2017.12 - EP); **C07D 285/135** (2013.01 - CN EP); **C07D 417/12** (2013.01 - CN EP)

Citation (search report)
• [I] WO 2011163594 A2 20111229 - ALKERMES INC [US], et al
• [I] US 2001002404 A1 20010531 - WEBB NIGEL L [US], et al
• [A] US 6051576 A 20000418 - ASHTON PAUL [US], et al
• [A] WO 9205786 A1 19920416 - MERCK & CO INC [US], et al
• [A] EP 0014642 A2 19800820 - MERCK & CO INC [US]
• [A] ILIES M ET AL: "Carbonic anhydrase inhibitors: sulfonamides incorporating furan-, thiophene- and pyrrole-carboxamido groups possess strong topical intraocular pressure lowering properties as aqueous suspensions", BIOORGANIC & MEDICINAL CHEMISTRY, PERGAMON, GB, vol. 8, no. 8, 1 August 2000 (2000-08-01), pages 2145 - 2155, XP027414362, ISSN: 0968-0896, [retrieved on 20000801]
• [A] AGRAWAL V K ET AL: "QSAR study on topically acting sulfonamides incorporating GABA moieties: A molecular connectivity approach", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, AMSTERDAM, NL, vol. 16, no. 7, 1 April 2006 (2006-04-01), pages 2044 - 2051, XP027966394, ISSN: 0960-894X, [retrieved on 20060401]
• [A] JENNIFFER I. ARENAS-GARCÍA ET AL: "Modification of the Supramolecular Hydrogen-Bonding Patterns of Acetazolamide in the Presence of Different Cocrystal Formers: 3:1, 2:1, 1:1, and 1:2 Cocrystals from Screening with the Structural Isomers of Hydroxybenzoic Acids, Aminobenzoic Acids, Hydroxybenzamides, Aminobenzamides, Nicotinic Acids," CRYSTAL GROWTH & DESIGN., vol. 12, no. 2, 1 February 2012 (2012-02-01), US, pages 811 - 824, XP055255392, ISSN: 1528-7483, DOI: 10.1021/cg201140g
• [A] LOFTSSON T ET AL: "The effect of water-soluble polymers on the aqueous solubility and complexing abilities of beta-cyclodextrin", INTERNATIONAL JOURNAL OF PHARMACEUTICS, ELSEVIER BV, NL, vol. 163, no. 1-2, 1 January 1998 (1998-01-01), pages 115 - 121, XP003003295, ISSN: 0378-5173, DOI: 10.1016/S0378-5173(97)00371-2
• See references of WO 2013167994A1

Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DOCDB simple family (publication)
WO 2013167994 A1 20131114; AU 2013257715 A1 20141127; AU 2013257715 B2 20160505; CA 2872978 A1 20131114; CN 104364241 A 20150218; EP 2847175 A1 20150318; EP 2847175 A4 20160420; JP 2015520748 A 20150723; SG 11201407317S A 20141230

DOCDB simple family (application)
IB 2013050899 W 20130203; AU 2013257715 A 20130203; CA 2872978 A 20130203; CN 201380030632 A 20130203; EP 13787577 A 20130203; JP 2015510896 A 20130203; SG 11201407317S A 20130203